We're delighted to announce key leadership appointments at Epitopea! Dr.Alan Rigby, a seasoned biotech entrepreneur and oncology innovator, joins us as our new CEO. Alan brings extensive experience, having raised over $250 million for early-stage oncology companies and previously leading HiberCell and Warp Drive Bio. We thank Dr.Jon Moore for his invaluable contributions and his ongoing commitment in the role of Chief Scientific Officer. We're also thrilled to welcome Dr.Michael Kalos, an internationally recognized expert in immunotherapy, as Chair of our Scientific and Clinical Advisory Boards. With these strategic appointments, we are poised for the next stage of growth as we advance our pipeline of groundbreaking RNA cancer immunotherapies into the clinic. 🔗Read the Press Release: https://lnkd.in/ecG6n3N3 Institute for Research in Immunology and Cancer of the Université de Montréal , Université de Montréal #Biotech #Innovation #Oncology #Cancer #RNA
About us
A newly established NewCo developing therapeutics targeting a novel class of tumour-specific antigen.
- Website
-
https://www.epitopea.com/
External link for Epitopea
- Industry
- Biotechnology
- Company size
- 11-50 employees
- Headquarters
- Montreal
- Type
- Privately Held
- Founded
- 2021
- Specialties
- TCR-T cells, Immuno-oncology, Vaccines, Bi-specifics, Splicing, Epigenetics, Oncology, T cell biology, and Antigen presentation
Locations
-
Primary
Get directions
Montreal, CA
-
Get directions
Cambridge, GB
Employees at Epitopea
Updates
-
Epitopea would like thank Immuno by Oxford Global for the invitation and chance to discuss our cancer vaccines. #cancervaccines #canceresearch #immunoncology
Catch our CEO, Dr Jonathan Kwok, and Co-founder and Preclinical VP, Dr Lian Ni Lee at Immuno by Oxford Global #Immuno2024 today where Dr Kwok has kicked off day two with a panel discussion on "Cancer Vaccines As Immuno Therapeutics" alongside Jon Moore and Benoît Van den Eynde. To round off a riveting two days of cutting-edge science, Dr Kwok will be presenting at 2:20 PM on how off-the-shelf precision vaccines can deliver affordable cancer therapies, and guide the conversation to explore mechanisms, platforms and current progress. #OGImmuno #Immuno24 #cancervaccines #cancerresearch #innovation #startups #oxforduniversity
-
-
Epitopea reposted this
Catch our CEO, Dr Jonathan Kwok, and Co-founder and Preclinical VP, Dr Lian Ni Lee at Immuno by Oxford Global #Immuno2024 today where Dr Kwok has kicked off day two with a panel discussion on "Cancer Vaccines As Immuno Therapeutics" alongside Jon Moore and Benoît Van den Eynde. To round off a riveting two days of cutting-edge science, Dr Kwok will be presenting at 2:20 PM on how off-the-shelf precision vaccines can deliver affordable cancer therapies, and guide the conversation to explore mechanisms, platforms and current progress. #OGImmuno #Immuno24 #cancervaccines #cancerresearch #innovation #startups #oxforduniversity
-
-
Congratulations to Eralda Kina and the teams in the labs of our scientific founders, Perreault Claude and Pierre Thibault, at Institute for Research in Immunology and Cancer of the Université de Montréal for their recent work published in the Journal of Clinical Investigation demonstrating that shared, non-mutated antigens are numerous in triple-negative tumors and represent attractive targets for immunotherapy. This extends Epitopea's leadership in the identification of this new class of targets across multiple liquid and solid tumors, and aligns with our mission to transform immunotherapy for cancer patients worldwide via accessible, cost-effective, off-the-shelf therapeutic vaccines targeting novel cancer-specific antigens. The full publication can be found at https://lnkd.in/gyxnnGkx. Don't miss the visual abstract which can be found at https://lnkd.in/gv7dUHYG! #breastcancer #cancer #cancerresearch #cancertreatment #cancerimmunotherapy
-
Congrats to our CBO, Steven Klein, for being nominated to the Board of Directors of the CQDM!
Press release: Appointments to the CQDM Board of Directors. CQDM is proud to announce the appointment of Carole Jabet, Scientific Director at the Fonds de recherche du Québec en Santé (FRQ-S) and Steven Klein, Chief Business Officer at Epitopea, to its board of directors. Also, Ms. Daria Riabinina, Director of Collaborative Research at the Ministère de l’Économie, de l’Innovation et de l’Énergie du Québec (MEIE) is appointed to the CQDM board of directors as an observer. These additions to the board of directors will bring a depth of experience and a wealth of knowledge to the life sciences sector, thereby consolidating and facilitating biopharmaceutical innovation in Quebec and Canada. Read the press release here: https://lnkd.in/eDhndHYx #lifesciences #biotechnology #drugdevelopment #innovation #funding #projects #medical #research #intelligenceartificielle #artificialintelligence #pharmaceutique #pharmaceutical #biopharma #biopharmaceutical #rna #rnatherapeutics #arn #boardofdirectors #nominations #appointments #conseiladministration Innovation, Science and Economic Development Canada Innovative Medicines Canada - Médicaments novateurs Canada The Coolest Hotspot Centech Mtl Canada Foundation for Innovation/Fondation canadienne pour l'innovation Ontario Bioscience Innovation Organization (OBIO) Life Sciences Ontario BioTalent Canada Life Sciences BC Bioscience Association Manitoba BioAlberta Life Sciences Nova Scotia MaRS Discovery District Canadian Alliance for Skills and Training in Life Sciences Vancouver Island Life Sciences (VILS)
-
-
Epitopea is pleased to announce the issuance of its first US patent covering our innovative approach to identify cryptic tumour-specific antigens. The shared nature of these antigens makes them ideal targets for off the shelf cancer vaccines and other immunotherapies. Epitopea exclusively licensed this IP from Universit�� de Montr��al, where the ground-breaking work was conducted by our scientific founders, Perreault Claude and Pierre Thibault, along with their teams, and with the support of IRICoR.